Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas

Pathology and Oncology Research

Volumn 5, Issue 3, 1999, Pages 187-191

  Tanyi, János ^a   Tory, Kálmán ^b   Rigó, János ^a   Nagy, Bálint ^a   Papp, Zoltán ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b N Gene R and D   (United States)

Author keywords

Epithelial ovarian tumor; Met proto oncogene; Mutation; Tyrosine kinase domain

Indexed keywords

PROTEIN TYROSINE KINASE; SCATTER FACTOR; TYROSINE KINASE RECEPTOR;

ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME 7; EXON; HUMAN; HUMAN TISSUE; KIDNEY CANCER; OVARY CARCINOMA; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTO ONCOGENE; TRISOMY;

EID: 0032712216     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1053/paor.1999.0219     Document Type: Article

References (27)

1. Bergerheim U SR. Chromosomal gains and losses in sporadic and hereditary papillary renal carcinomas by comperative genomic hybridization. J Urol. 155:1996;543-543.
2. Bladt F, Rietmacher D, Isenmann S. Essential role for the c-Met receptor in the migration of myogenic precursor cells into the limb bud. Nature. 376:1995;768-771.
3. Bottaro D P, Rubin J S, Faletto D L. Identification of the hepatocyte growth factor receptor as the c-Met proto-oncogene product. Science. 251:1991;802-804.
4. Chi-Ho Mok S, Bell D A, Knapp R C. Mutation of K-ras protooncogene in human ovarian tumors of borderline malignancy. Cancer Res. 53:1993;1489-1492.
5. Di Renzo M F, Olivero M, Katsaros D. Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer. 58:1994;658-662.
6. Di Renzo M F, Olivero M, Ferro S. Overexpression of the c-Met/Hgf receptor gene in human thyroid carcinomas. Oncogene. 7:1992;2549-2553.
7. Ebert M, Yokohama M, Friess H. Coexpression of the c-Met proto-oncogene and hepatocyta growth factor in human pancreatic cancer. Cancer Research. 54:1994;5775-5778.
8. Giordano S, Ponzetto C, Di Renzo M F. Tyrosine kinase receptor indistinguishable from the c-Met protein. Nature. 339:1989;155-156.
9. Hofstra R M, Landsvater R M, Ceccherini I. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 367:1994;375-376.
10. Jeffers M, Rong S, Vande Woude G. Enhanced tumorigenicity and invasion-Metastasis by hepatocyte growth factor/scatter factor-Met signalling in human cells concomittant with induction of the urokinase proteolysis network. Mol Cell Biol. 16:1996;1115-1125.
11. Kovacs G. Molecular cytogenetics of renal tumors. Adv Cancer Res. 62:1993;89-124.
12. Liang J C, Kurzrock R, Gutterman J U. Trisomy 12 correlates with elevated expression of p21ras in human adenosquamosus carcinoma of the lung. Cancer. 23:1986;183-188.
13. Naldini L, Weidner K M, Vigna E. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO. 10:1991;2867-2878.
14. Natali P G, Prat M, Nicotra M R. Overexpression of the Met/HGF receptor in renal cell carcinomas. Int J Cancer. 69:1996;212-217.
15. Nusrat A, Parkos C A, Bacarra A E. Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarisation of c-Met receptor in transformed and natural intestinal epithelia, and induction of rapid wound repair in a transformed model epithelium. J Clin Invest. 93:1994;2056-2065.
16. Pejovic T, Iosif C S, Mitelman F. Karyotypic characteristics of borderline malignant tumors of the ovary. Cancer Genet Cytogenet. 92:1996;95-98.
17. Perez R P, Godwin A K, Hamilton T C. Ovarian cancer biology. Semin Oncol. 18:1991;186-204.
18. Persons D L, Hartmann L C, Herath J F. Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas. Am J Pathol. 142:1993;733-741.
19. Prat M, Narsimhan R P, Crepladi T. The receptor encoded by the human c-Met oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer. 49:1991;323-328.
20. Santoro M, Carlomagno F, Romano A. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science. 267:1995;381-383.
21. Schmidt L, Fuh-Mei Duh, Fan C. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genet. 16:1997;68-73.
22. Serov S F, Scully R E, Sobin L H. International histological classification and staging of tumors. Histologic typing of ovarian tumors. Geneva: World Health Organization. 9:1973.
23. Sonnenberg E, Meyer D, Weidner K M. Scatter factor/hepatocyte growth factor and its receptor, the c-Met tyrosine, can mediate a signal exchange between mesenchyme and epithelial cell during mouse development. J Cell Biol. 123:1993;223-235.
24. Tanyi J, Tory K, Rigó J. Mutation in the tyrosine kinase domain of MET proto-oncogene in a sporadic Epithelial ovarian cancer. (submitted). J Reprod Med. 1999.
25. Weidner K M, Sachs M, Birchmeier W J. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. Cell Biol. 121:1993;145-154.
26. Woolf A S, Kolatsi-Joannou M, Hardman P. Roles of hepatocyte growth factor/scatter factor and the Met receptor in the early development of the Metanephros. J Cell Biol. 128:1995;171-184.
27. Zhuang Z, Park W S, Pack S. Trisomy 7-harbouring non-random duplication of the mutatnt MET allele in hereditary papillary renal carcinomas. Nat Genet. 20:1998;66-69.